Stockscreener 앱 받기
26.29
0.61%
0.16
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Rigel Pharmaceuticals (RIGL) Q4 earnings miss estimates - MSN
Rigel Pharmaceuticals Q4 2025 earnings preview - MSN
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors - TipRanks
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure - Fierce Biotech
Rigel Pharmaceuticals shows rising relative strength; still shy of key benchmark - MSN
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Rigel enrols first subject in R289 Phase Ib expansion for MDS - MSN
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update - Quantisnow
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential? - MSN
Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats - MSN
RIGL stock rises 59% in a year: Time to buy, hold or sell? - MSN
Rigel Pharmaceuticals: Growing Where It Matters (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL) earnings expected to grow: Should you buy? - MSN
Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results - Sahm
Analysts Set Expectations for RIGL Q3 Earnings - MarketBeat
Surging Earnings Estimates Signal Upside for Rigel (RIGL) Stock - MSN
Rigel Pharmaceuticals (RIGL) EPS Spike On Non Cash Gains Challenges Bullish Narratives - Sahm
Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty - The Globe and Mail
Brokers Offer Predictions for RIGL Q1 Earnings - MarketBeat
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Rigel Pharmaceuticals (RIGL) Projects Revenue Decline for 2026 - GuruFocus
Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $71 - 富途牛牛
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights: Record Net Income and Strategic Growth Initiatives - GuruFocus
Rigel Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress - Yahoo Finance
Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect - AlphaStreet
Cumberland (CPIX) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Rigel’s Q4 2025 shows robust growth - Investing.com
Earnings call transcript: Rigel’s Q4 2025 shows robust growth By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RIGL) 2026-03-03 - Seeking Alpha
RIGL: Record sales and net income in 2025, with strong growth outlook and pipeline progress for 2026 - TradingView
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates - Bitget
Rigel Pharma (RIGL) Earnings Call Transcript - AOL.com
Rigel Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Rigel Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rigel Pharmaceuticals Q4 Earnings, Revenue Rise; 2026 Revenue Outlook Set - marketscreener.com
Rigel Pharmaceuticals (RIGL) Projects FY26 Revenue Growth - GuruFocus
Earnings Summary: Rigel Pharmaceuticals Q4Rigel Pharmaceuticals (NASDAQ:RIGL) - Benzinga
Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Quarterly Earnings Results, Misses Estimates By $0.19 EPS - MarketBeat
RIGL: Record 2025 revenue and net income, with 2026 outlook for continued growth and pipeline progress - TradingView
Rigel Pharmaceuticals reports Q4 EPS $13.54 with items, consensus $1.20 - TipRanks
Rigel (NASDAQ: RIGL) boosts blood cancer drug sales and advances pipeline - Stock Titan
Rigel: Q4 Earnings Snapshot - marketscreener.com
RIGL: Record 2025 revenue and net income, strong product growth, and positive 2026 outlook - TradingView
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - marketscreener.com
1.82%
자본화:
|
볼륨(24시간):